表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体（EGFR）野生型非小细胞肺癌患者：没完没了的故事 - Suppr

Suppr

超能文献

Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story.

作者信息

Gelsomino Francesco, Agustoni Francesco, Niger Monica, Valota Marika, Haspinger Eva R

机构信息

Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.

出版信息

J Clin Oncol. 2013 Sep 10;31(26):3291-3. doi: 10.1200/JCO.2013.50.2617. Epub 2013 Aug 12.

DOI:10.1200/JCO.2013.50.2617

PMID:23940223

Abstract

摘要

相似文献

Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story.表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体（EGFR）野生型非小细胞肺癌患者：没完没了的故事

J Clin Oncol. 2013 Sep 10;31(26):3291-3. doi: 10.1200/JCO.2013.50.2617. Epub 2013 Aug 12.

Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展

J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.晚期非小细胞肺癌患者临床预后因素与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）疗效的相关性：94例EGFR突变患者的回顾性评估

Oncotarget. 2017 Jan 10;8(2):3412-3421. doi: 10.18632/oncotarget.13787.

[Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].[第三代表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌的机制及临床疗效]

Zhonghua Zhong Liu Za Zhi. 2017 Jun 23;39(6):401-404. doi: 10.3760/cma.j.issn.0253-3766.2017.06.001.

Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.高剂量表皮生长因子受体酪氨酸激酶抑制剂与序贯多西他赛对野生型表皮生长因子受体非小细胞肺癌细胞裸鼠异种移植瘤的抗肿瘤活性

Oncotarget. 2017 Feb 7;8(6):9134-9143. doi: 10.18632/oncotarget.13327.

Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.表皮生长因子受体抑制剂在表皮生长因子受体野生型非小细胞肺癌中的作用。

J Clin Oncol. 2013 Mar 10;31(8):1061-9. doi: 10.1200/JCO.2012.43.4522. Epub 2013 Feb 11.

Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.表皮生长因子受体酪氨酸激酶抑制剂用于先前治疗过的具有野生型表皮生长因子受体的晚期非小细胞肺癌

Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18.

Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.解决非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂耐药问题。

Expert Rev Respir Med. 2016;10(5):547-56. doi: 10.1586/17476348.2016.1164603. Epub 2016 Mar 28.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.表皮生长因子受体酪氨酸激酶抑制剂作为非小细胞肺癌的初始治疗：重点关注表皮生长因子受体突变检测和突变阳性患者。

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.

引用本文的文献

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.医保患者转移性肺腺癌中表皮生长因子受体突变检测和靶向治疗的利用和费用。

BMC Health Serv Res. 2022 Apr 9;22(1):470. doi: 10.1186/s12913-022-07857-y.

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth.发现一种新型 EGFR 配体 DPBA，可降解 EGFR 并抑制 EGFR 阳性 NSCLC 的生长。

Signal Transduct Target Ther. 2020 Oct 9;5(1):214. doi: 10.1038/s41392-020-00251-2.

Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.基于其激酶非依赖性功能对癌症中表皮生长因子受体（EGFR）的重新思考

Front Oncol. 2019 Aug 23;9:800. doi: 10.3389/fonc.2019.00800. eCollection 2019.

Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt.靶向降低表皮生长因子受体（EGFR）蛋白，而非抑制其激酶活性，可通过激活哺乳动物雷帕霉素靶蛋白复合物2（mTORC2）和蛋白激酶B（Akt）诱导癌细胞的线粒体自噬和死亡。

Oncogenesis. 2018 Jan 23;7(1):5. doi: 10.1038/s41389-017-0021-7.

Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits.仅能提供无进展生存期的药物的治疗目标被患者误解，并且肿瘤学家可能对可能的益处过于乐观。

Support Care Cancer. 2017 Jan;25(1):237-244. doi: 10.1007/s00520-016-3408-7. Epub 2016 Sep 13.

Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure.在表皮生长因子受体-酪氨酸激酶抑制剂治疗失败后，西妥昔单抗联合化疗对晚期非小细胞肺癌患者有益。

Int J Clin Exp Med. 2015 Sep 15;8(9):16140-8. eCollection 2015.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.热休克蛋白90（HSP90）抑制剂ganetespib增强了表皮生长因子受体（EGFR）酪氨酸激酶抑制剂对突变型和野生型非小细胞肺癌的抗肿瘤活性。

Target Oncol. 2015 Jun;10(2):235-45. doi: 10.1007/s11523-014-0329-6. Epub 2014 Aug 1.

Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.表皮生长因子受体（EGFR）信号调控的miR-203缺失促进前列腺癌骨转移及对酪氨酸激酶抑制剂耐药。

Oncotarget. 2014 Jun 15;5(11):3770-84. doi: 10.18632/oncotarget.1994.

Molecular pathways and therapeutic targets in lung cancer.肺癌中的分子途径与治疗靶点

Oncotarget. 2014 Mar 30;5(6):1392-433. doi: 10.18632/oncotarget.1891.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验